Web Results

Thalidomide in induction treatment increases the very good partial ...


Lokhorst HM(1), Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R ... patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs.

Administration of bortezomib before and after autologous stem cell ...


Dec 8, 2011 ... Neben K(1), Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, ... Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, ... (1)Department of Internal Medicine V, University of Heidelberg, ...

Bortezomib Induction and Maintenance Treatment in Patients With ...


Aug 20, 2012 ... Results of these subgroups are presented in detail in Neben et al. ... In patients with normal serum creatinine, PFS (median 31 v 35 months; .... Conception and design: Pieter Sonneveld, Ingo G.H. Schmidt-Wolf, ... Administrative support: Bronno van der Holt, Laila el Jarari, Uta Bertsch, Henk M. Lokhorst, ...

PDF(228K) - Wiley Online Library


Jun 19, 2012 ... et al, 2008a; Spencer et al, 2009; Lokhorst et al, 2011; Mor- gan et al, 2012). This benefit is ..... pared with a historical control group of patients (72% vs. 51%). ..... Sonneveld, P., Scmidt-Wolf, I., van der Holt, B. & el Jarari, L.

Comment on “Outcomes of autologous transplantation for multiple ...


Jul 8, 2014 ... H.M. Lokhorst, I. Schmidt-Wolf, P. Sonneveld, B. van der Holt, H. Martin, R. Barge, ... M. Macro, M. Divine, Y. Uzunhan, A. Jaccard, D. Bouscary, V. Leblond, et al. ... See paper by Crusoe EQ et al, on Rev Bras Hematol Hemoter.

Phylogeny of Oedogoniales, Chaetophorales and ... - Annals of Botany


with CW rotation (Bakker and Lokhorst, 1984; Watanabe and Floyd .... structing phylogeny (Wolf et al., 2005, 2008; Seibel et al.,. 2006 ... using Sequencher (v.

Multiple Myeloma: Future Directions in Autologous Transplantation ...


Jan 3, 2013 ... Section V: Multiple Myeloma .... Richardson et al. [30] .... D or Dex indicates dexamethasone; Len or R, lenalidomide; P or V, bortezomib; C, .... Lokhorst et al. ..... 28; P. Sonneveld, I.G. Schmidt-Wolf, B. van der Holt, et al.

new developments in the treatment of patients with multiple myeloma


(ns). Lokhorst et al. 20098. VAD vs TAD. 79 vs 88%. 25 vs 34. 60 vs 73 (ns). T 200 mg ... thalidomide had a median OS after relapse of 20 months vs. 31 months  ...

Optimal maintenance and consolidation therapy for multiple ... - KJIM


Sep 1, 2016 ... In the IFM 2008 study, Roussel et al. [24] assessed the ... et al. (2013) [21], Phase III, Bortezomib consolidation vs. no consolidation, 187 vs. ... Lokhorst et al. (2010) [17] ..... Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al.

The Role of Bortezomib, Thalidomide and Lenalidomide in the ...


Dec 23, 2012 ... The most recent trial in this area, published by Lokhorst et al.,[11] found that the median .... Table V. Thalidomide, lenalidomide or bortezomib: clinical trials and outcomes in ..... Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al.

More Info

Bortezomib induction and maintenance treatment in patients - NCBI


Jul 16, 2012 ... Sonneveld P(1), Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, ... Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. ... induction (15% v 31%; P < .001) and bortezomib maintenance (34% v 49%; P < .001).

Leukemia - Monoclonal antibodies in the treatment of multiple ...


Oct 9, 2015 ... Median PFS was also longer in the high-dose cohort (23 vs 14.9 ...... Plesner T, Arkenau HT, Lokhorst HM, Gimsing P, Krejcik J, Lemech C et al. ..... Chanan- Khan A, Wolf JL, Garcia J, Gharibo M, Jagannath S, Manfredi D et al.

A randomized phase 3 study on the effect of thalidomide combined ...


... vs 1 vs 2-3), stage according to Salmon and Durie (II vs III), immunoglobulin (Ig ) isotype (IgA, ..... Correspondence: Henk M. Lokhorst, Department of Hematology , University Medical Center ... Lokhorst HM,; Schmidt-Wolf I,; Sonneveld P,; et al.